Connection Between Epigenome, Selective Mutability, Evolution, and Human Disease
Li, Harris et al., PLoS Genetics
Researchers at the Baylor College of Medicine and elsewhere propose a "connection between the epigenome, selective mutability, evolution, and human disease" based on the findings of their study on associations of structural mutability with germline DNA methylation and with non-allelic homologous recombination mediated by low-copy repeats. "Combined evidence from four human sperm methylome maps, human genome evolution, structural polymorphisms in the human population, and previous genomic and disease studies consistently points to a strong association of germline hypomethylation and genomic instability," the Baylor-led team writes.
Study Shows Oncotype DX and PAM50 Breast Cancer Tests Disagree on Intermediate Risk Group
May 18, 2011
Two genomic tests for cancer risk recurrence -- Oncotype DX and PAM50 -- show reasonable agreement on high- and low-risk categories but do not agree in their classification of intermediate-risk patients, according to a recent comparison of the assays.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register quickly here.
New to GenomeWeb? Register quickly here.
Related Stories
- Oncotype DX Study Raises Questions About RT-PCR Testing for HER2 Expression
December 1, 2011 / PCR Insider - NanoString Study Suggests PAM50 Recurrence Test Provides Advantages over Oncotype DX
December 14, 2011 / Pharmacogenomics Reporter - St. Gallen Experts Recommend Oncotype DX for Chemoprediction; Support Breast Cancer Subtyping
July 27, 2011 / Pharmacogenomics Reporter - Genomic Health Partners with OncoMed to Grow Companion Dx, NGS Reach
May 9, 2012 / Pharmacogenomics Reporter - Reporting Another Profitable Year, Genomic Health Considers Prostate Cancer Dx Next Big Opportunity
February 8, 2012 / Pharmacogenomics Reporter